holmen lab banner


View all publications in Google Scholar or PubMed.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray, Matthew A. Williams, Stephanie M. Meek, Randy C. Bowen, Kenneth F. Grossmann, Robert H. I. Andtbacka, Tawnya L. Bowles, John R. Hyngstrom, Sancy A. Leachman, Douglas Grossman, Glen M. Bowen, Sheri L. Holmen, Matthew W. VanBrocklin, Gita Suneja and Hung T. Khong
Oncotarget, Advance Publications 2016
Melanoma metastases caught in the AKT
David A. Kircher, Rowan A. Arave, Joseph H. Cho & Sheri L. Holmen
Molecular & Cellular Oncology, 3:2, e1128516, DOI:10.1080/23723556.2015.1128516

In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation
Gemma L. Robinson, Beatrice Philip, Matthew R. Guthrie, James E. Cox, James P. Robinson, Matthew W. VanBrocklin, Sheri L. Holmen
Cancer Research Frontiers. 2016 May; 2(2): 311-329. doi: 10.17980/2016.311

AKT1 Activation Promotes Development of Melanoma Metastases
Joseph H. Cho, James P. Robinson, Rowan A. Arave, Matthew W.,VanBrocklin, Martin McMahon and Sheri L. Holmen
Cell Reports 13, 898-905, November3 , 2015
The BRAF kinase domain promotes the development of gliomas in vivo
Clifford H. Shin, Allie H. Grossmann, Sheri L. Holmen and James P. Robinson
Genes & Cancer, Vol. 6 (1-2), January 2015

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.
Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.
Genes Cancer. 2013 Nov;4(11-12):476-85.

Meeting report: The future of preclinical mouse models in melanoma treatment is now.
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M.
Pigment Cell Melanoma Res. 2013 Jul;26(4):E8-E14.

IDH1 and IDH2 mutations in gliomas.
Cohen AL, Holmen SL, Colman H.
Curr Neurol Neurosci Rep. 2013 May;13(5):345. Review.

Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D.
J Invest Dermatol. 2013 Apr;133(4):1043-51.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.
Neuro Oncol. 2012 Jan;14(1):34-42.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.
Oncogene. 2011 Mar 17;30(11):1341-50.

Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.
McKinney AJ, Holmen SL.
Chin J Cancer. 2011 Mar;30(3):153-62. Review.

Akt signaling is required for glioblastoma maintenance in vivo.
Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL.
Am J Cancer Res. 2011;1(2):155-167.

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL.
Pigment Cell Melanoma Res. 2010 Aug;23(4):531-41.

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.
Oncogene. 2010 Jan 21;29(3):335-44.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.
Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.
Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60.

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL.
Cancer Res. 2009 Mar 1;69(5):1985-94.

Inhibition of Marek's disease virus replication by retroviral vector-based RNA interference.
Chen M, Payne WS, Hunt H, Zhang H, Holmen SL, Dodgson JB.
Virology. 2008 Aug 1;377(2):265-72.

Inhibition of avian leukosis virus replication by vector-based RNA interference.
Chen M, Granger AJ, Vanbrocklin MW, Payne WS, Hunt H, Zhang H, Dodgson JB, Holmen SL.
Virology. 2007 Sep 1;365(2):464-72.

Differential oncogenic potential of activated RAS isoforms in melanocytes.
Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.
Oncogene. 2007 Jul 5;26(31):4563-70.

APC inhibits ERK pathway activation and cellular proliferation induced by RAS.
Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO, Chung KC, Surh YJ, Choi KY.
J Cell Sci. 2006 Mar 1;119(Pt 5):819-27.

Essential role for Ras signaling in glioblastoma maintenance.
Holmen SL, Williams BO.
Cancer Res. 2005 Sep 15;65(18):8250-5.

Essential role of beta-catenin in postnatal bone acquisition.
Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO.
J Biol Chem. 2005 Jun 3;280(22):21162-8.

Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.
Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML.
Mol Cell Biol. 2005 Jun;25(12):4946-55.

Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein.
Holmen SL, Robertson SA, Zylstra CR, Williams BO.
Biochem Biophys Res Commun. 2005 Mar 11;328(2):533-9.

Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG.
Cancer Res. 2005 Mar 1;65(5):2009-17.

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.
Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO.
J Bone Miner Res. 2004 Dec;19(12):2033-40.

Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.
Bromberg-White JL, Webb CP, Patacsil VS, Miranti CK, Williams BO, Holmen SL.
J Virol. 2004 May;78(9):4914-6.

A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate beta -catenin-dependent signaling.
Holmen SL, Salic A, Zylstra CR, Kirschner MW, Williams BO.
J Biol Chem. 2002 Sep 20;277(38):34727-35.

Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor.
Holmen SL, Melder DC, Federspiel MJ.
J Virol. 2001 Jan;75(2):726-37.

Selection of a subgroup A avian leukosis virus [ALV(A)] envelope resistant to soluble ALV(A) surface glycoprotein.
Holmen SL, Federspiel MJ.
Virology. 2000 Aug 1;273(2):364-73.

Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.
Holmen SL, Salter DW, Payne WS, Dodgson JB, Hughes SH, Federspiel MJ.
J Virol. 1999 Dec;73(12):10051-60.

Efficient lipid-mediated transfection of DNA into primary rat hepatocytes.
Holmen SL, Vanbrocklin MW, Eversole RR, Stapleton SR, Ginsberg LC.
In Vitro Cell Dev Biol Anim. 1995 May;31(5):347-51.

These publications can be downloaded for personal use and are not intended for redistribution.